Search Results - james+yang

16 Results

Sort By:

Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia

Summary: The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. Description of Technology: Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis...

Published: 4/10/2026 | Updated: 4/10/2026 | Inventor(s): Vid Leko, Aidan Pursley, Kenichi Hanada, Zhiya Yu, Catherine Ade, James Yang

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Multi-parametric Acoustic, Optical and Mechanical Imaging of Cervical Tissue Insufficiencies to Predict Preterm Birth

An enhanced image-guidance system that integrates ultrasound and photoacoustic into existing ablation systems to provide an enhanced image-guidance system for identification of cervical tissue changes during pregnancy and postpartum. Technology Summary Preterm delivery is a main cause of perinatal morbidity and mortality worldwide, which is associated...

Published: 10/1/2025 | Updated: 9/10/2025 | Inventor(s): Mohammad Mehrmohammadi, Sonia Hassan, Edgar Hernandez-Andrade, Yan Yan, Maryam Basij

Keywords(s): Driving Lifelong Health

Category(s): Technology Category > Women's Health, Technology Category > Medical Devices, Technology Category > Life Science, Technology Category > Imaging, Technology Category > Acoustics

T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use

Summary: The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research. Description of Technology: Tumor-specific mutated proteins can create immunogenic, mutation-containing “neoepitopes” which are attractive...

Published: 4/16/2026 | Updated: 1/16/2024 | Inventor(s): Catherine Ade, Zhiya Yu, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s):

Category(s): TherapeuticArea, Application, Application > Research Materials, Collaboration Sought > Licensing

T cell Receptors Which Recognize Mutated EGFR

Abstract: Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in cell growth and proliferation. Mutations in this protein can lead to overexpression, causing several types of cancer; notably, non-small cell lung cancer (NSCLC). For example, mutations in EGFR are found in up to 50% of NSCLC patients and the E746-A750 deletion...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Kenichi Hanada, Chihao Zhao, Anna Pasetto, James Yang

Keywords(s): EGFR mutation, Epidermal Growth Factor Receptor, Hanada, Immunotherapy, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Summary: NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs. Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer

Abstract: The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments. Researchers at the NCI have developed...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Kenichi Hanada, Qiong Wang, James Yang, Zhiya Yu

Keywords(s): act, adoptive cell therapy, Human Thyroglobulin, Immunotherapy, METASTATIC, T-cell Receptors, TCR, TCRs, Tg, THYROID CANCER, Yang

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy

Summary: The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation. Description of Technology: BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Zhiya Yu, Catherine Ade, Matthew Sporn, James Yang, Kenichi Hanada

Keywords(s): BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen

Abstract: Scientists at the NCI's Surgery Branch have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The anti-CD70 CARs are hybrid proteins consisting of a receptor...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Qiong Wang, Zhiya Yu, James Yang

Keywords(s): CARS, CD70, chimeric antigen receptor, T-cell reprogramming

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations

Abstract: Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis. Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable. ...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Qiong Wang, James Yang, Zhiya Yu

Keywords(s): Colorectal, Immunotherapy, KRAS, LUNG, oncogenesis, PANCREAS, PROSTATE, T cell, TCR

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

2022-216 Electrode for Rechargeable Batteries that Resists Dendrite Growth

Summary: UCLA researchers in the Department of Material Science and Engineering have developed electrodes for rechargeable batteries which resist dendrite growth. Background: Rechargeable batteries have attracted attention due to their wide array of applications and environmental benefits. Rechargeable metal-ion batteries, such as lithium-ion batteries,...

Published: 3/19/2025 | Updated: 6/30/2022 | Inventor(s): Yang Yang, Xiaochun Li

Keywords(s): Alloy, Dendrite, Electrode, Lithium Battery, Lithium-Ion Battery, Nanoelectronics, Nanoparticle, Rechargeable Battery, Rechargeable Battery Thermal Conductivity

Category(s): Materials > Semiconducting Materials, Energy & Environment > Energy Efficiency, Energy & Environment > Energy Storage, Electrical > Electronics & Semiconductors, Energy & Environment > Energy Storage > Batteries

1 2